August 29, 2025
COPENHAGEN, August 2025, Amass, the AI-native intelligence platform, just announced €1.4 million in pre-seed funding in a highly competitive round led by Giant Ventures, and joined by Kost Capital and Dr. Christian Thirion, founder and CEO of Sirion Biotech GmbH, acquired by Perkin Elmer, Dr. Christian Thirion, and EIFO, Danish Sovereign Wealth Fund - Denmark’s largest life science investor.
Founded in Copenhagen’s dense life sciences ecosystem, Amass helps research teams navigate and connect the world’s fragmented scientific knowledge - spanning not just public literature and patents, but also internal research notebooks, experiment summaries, and proprietary datasets.Their customers include pharmaceutical, biosciences, and biosolutions companies, as well as research institutions and universities.
Amass applies domain-specific AI models to structure and cross-link internal scientific data with trillions of data points from external sources such as literature, patents, publications, trials, regulatory filings and more.
Developed in collaboration with hundreds of researchers from biotech start-ups, universities and big pharma, Amass enables researchers to build their own tools and triangulate across data sources, trace evidence, and make confident, evidence-backed decisions. Making and accelerating science.
Amass is co-founded by entrepreneur and Antler venture advisor, Henrik Jensen, partnered with former Novo Nordisk, and former Head of AI at Corti, Alexander Junge - whose research on building knowledge discovery tools for researchers received more than 13 thousand citations.
“Scientific knowledge is growing faster than most teams can parse, let alone act on,” says Henrik Jensen, Co-founder and CEO of amass. “We’ve built Amass with researchers, for researchers, and what we’re seeing now is strong pull from across the life sciences. This funding lets us scale to meet that demand.”
Amass' vision is to become the default intelligence layer for global R&D, a must-have platform in every research-driven organisation. Life sciences innovation cycles will compress dramatically, enabling faster, cheaper development of drugs, diagnostics, and biosolutions. With a persistent, AI-curated map of the world’s scientific knowledge, Amass will be positioned as a category-defining infrastructure company at the intersection of life sciences and AI.
“amass is solving one of the most foundational bottlenecks in life sciences: the ability to connect dots across a growing universe of siloed knowledge,” says Tommy Ahlers, Partner at Giant Ventures. “Their approach is technically differentiated, deeply validated by users, and globally relevant.”
“We were impressed by amass’s early traction,” Bodil Sidén adds, General Partner at Kost Capital. “Their product is clearly built by and for researchers, and it addresses a fundamental need across not only drug discovery and diagnostics but also extends to biosolutions, food and essentially across the ecosystem. Having seen what they can do, we believe Amass can become a critical infrastructure and application layer in the life sciences.”
The funding will be used to expand the team, extend product capabilities, accelerate the work on their proprietary LifeSciEmbed model and to scale the commercial operations to meet a growing enterprise demand across Europe and beyond, in their quest to connect the world’s scientific community